Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $35.67 Consensus PT from Analysts
Shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The […]
Shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The […]
